37
Participants
Start Date
June 1, 2023
Primary Completion Date
February 4, 2026
Study Completion Date
February 4, 2026
CV09050101 mRNA vaccine (CVGBM) 12 μg
CVGBM will be administered as an IM injection.
CV09050101 mRNA vaccine (CVGBM) 25 μg
CVGBM will be administered as an IM injection.
CV09050101 mRNA vaccine (CVGBM) 50 μg
CVGBM will be administered as an IM injection.
CV09050101 mRNA vaccine (CVGBM) 100 μg
CVGBM will be administered as an IM injection.
CV09050101 mRNA vaccine RDE 100 μg
CVGBM will be administered as an IM injection.
CV09050101 mRNA vaccine (CVGBM) 6 μg
CVGBM will be administered as an IM injection.
Universitair Ziekenhuis Brussel - PPDS, Brussels
CHU de Liège, Liège
Universitätsklinikum Freiburg, Freiburg im Breisgau
University Clinic Heidelberg, Heidelberg
Universitätsmedizin Mannheim, Mannheim
Universitätsklinikum Tübingen, Tübingen
University Clinic Regensburg, Regensburg
Universitätsklinikum Frankfurt, Frankfurt am Main
Universitätsklinikum Bonn, Bonn
University Hospital Essen, Essen
Universitatsklinikum Leipzig, Leipzig
Neurosurgical Clinic at the LMU Munich, München
Erasmusmc Cancer institute, Rotterdam
Lead Sponsor
CureVac
INDUSTRY